Endomimetics™ strives to revolutionize procedural and implantable device outcomes by leveraging cutting-edge peptide-based nanotechnologies, such as its proprietary Bionanomatrix™, to promote healing, enhance device longevity, and improve patient care across medical applications.
We are a team of scientists, innovators, and business leaders with a shared goal of changing the face of healing. Our Bionanomatrix™ technology and innovations were spun out of the University of Alabama at Birmingham, paving the way to the success of Endomimetics™.
Pursuing groundbreaking advancements in nanotechnology to improve patient outcomes and medical device performance.
Prioritizing safety, healing, and long-term health benefits in every product.
Upholding rigorous research and development standards to create reliable, evidence-based technologies.
Fostering partnerships with researchers, clinicians, and industry leaders to drive transformative solutions.
Maintaining transparency, ethical practices, and a commitment to improving global healthcare.
At Endomimetics™, we focus on developing innovative peptide-based coatings and gels like Bionanomatrix™ to enhance the safety and longevity of implantable medical devices. Our operations emphasize precision-driven research, leveraging multidisciplinary expertise in biomedical engineering and materials science. Through clinical collaboration and feedback, we tailor solutions to address unmet medical needs. We ensure our products meet stringent quality standards while actively pursuing regulatory approvals. Transparency, ethical conduct, and a commitment to advancing healthcare are the cornerstones of our daily operations.
Endomimetics™ has its origins in the collaboration between two bioengineering visionaries: Brigitta Brott, M.D., an interventional cardiologist at UAB and Ho-Wook Jun, Ph.D., UAB Biomedical Engineering faculty. They developed a novel bionanomatrix coating to inhibit blood clot formation and renarrowing of arteries while enhancing the healing process for patients with coronary stents.
In an effort to bring the product to market, the pair applied for and received a Wallace Coulter Foundation grant, which matches biomedical faculty with a clinician/researcher. After attending the Coulter Foundation’s business training and an “Idea to IPO” class in the UAB School of Business, Brott and Jun determined the fastest way to get the coating to market was to form a company and partner with device manufacturers. Endomimetics was subsequently founded in November 2009 and now resides at Station 41.
Bionanomatrix coating for brain aneurysm coils to enhance healing
Nitric oxide releasing nanomatrix wrap to enhance dialysis fistula maturation
Coating to enhance endothelialization after left atrial appendage closure
Nitric oxide releasing nanomatrix to enhance dialysis fistula maturation. Successful grant completion in 2018
Enhanced endothelialization of nanomatrix coated flow diverter for intracranial aneurysms
Nitric oxide releasing bionanomatrix to enhance dialysis fistula maturation
Dual-action drug coated balloon to mitigate neointimal hyperplasia and promote endothelialization
Endomimetics™ announces a research collaboration agreement with BISCO, Inc., to support the development of a dental application of Bionanomatrix™
Bionanomatrix coating to enhance antibacterial effects while reducing inflammation of knee joint implants
Support the development and evaluate the potential of Bionanomatrix™ to reduce infectious and inflammatory complications of knee arthroplasty
Enhanced endothelialization of nanomatrix coated flow diverter for intracranial aneurysms
Atherosclerosis assay development for drug efficacy and cytotoxicity screening
We are developing medical breakthroughs with our proprietary Bionanomatrix™ technology and invite you to join our transformative efforts. Your partnership can accelerate these exciting developments, helping us push the boundaries of medical technology and improve healthcare for everyone.
